» Articles » PMID: 38774758

METTL3 Deficiency Aggravates Hepatic Ischemia/Reperfusion Injury in Mice by Activating the MAPK Signaling Pathway

Overview
Journal Int J Med Sci
Specialty General Medicine
Date 2024 May 22
PMID 38774758
Authors
Affiliations
Soon will be listed here.
Abstract

Inflammatory responses, apoptosis, and oxidative stress, are key factors that contribute to hepatic ischemia/reperfusion (I/R) injury, which may lead to the failure of liver surgeries, such as hepatectomy and liver transplantation. The N6-methyladenosine (mA) modification has been implicated in multiple biological processes, and its specific role and mechanism in hepatic I/R injury require further investigation. Dot blotting analysis was used to profile mA levels in liver tissues at different reperfusion time points in hepatic I/R mouse models. Hepatocyte-specific METTL3 knockdown (HKD) mice were used to determine the function of METTL3 during hepatic I/R. RNA sequencing and western blotting were performed to assess the potential signaling pathways involved with the deficiency of METTL3. Finally, AAV8-TBG-METTL3 was injected through the tail vein to further elucidate the role of METTL3 in hepatic I/R injury. The mA modification levels and the expression of METTL3 were upregulated in mouse livers during hepatic I/R injury. METTL3 deficiency led to an exacerbated inflammatory response and increased cell death during hepatic I/R, whereas overexpression of METTL3 reduced the extent of liver injury. Bioinformatic analysis revealed that the MAPK pathway was significantly enriched in the livers of METTL3-deficient mice. METTL3 protected the liver from I/R injury, possibly by inhibiting the phosphorylation of JNK and ERK, but not P38. METTL3 deficiency aggravates hepatic I/R injury in mice by activating the MAPK signaling pathway. METTL3 may be a potential therapeutic target in hepatic I/R injury.

References
1.
Zeng C, Huang W, Li Y, Weng H . Roles of METTL3 in cancer: mechanisms and therapeutic targeting. J Hematol Oncol. 2020; 13(1):117. PMC: 7457244. DOI: 10.1186/s13045-020-00951-w. View

2.
Shi W, Zheng Y, Luo S, Li X, Zhang Y, Meng X . METTL3 Promotes Activation and Inflammation of FLSs Through the NF-κB Signaling Pathway in Rheumatoid Arthritis. Front Med (Lausanne). 2021; 8:607585. PMC: 8290917. DOI: 10.3389/fmed.2021.607585. View

3.
Su X, Shen Y, Jin Y, Kim I, Weintraub N, Tang Y . Aging-Associated Differences in Epitranscriptomic m6A Regulation in Response to Acute Cardiac Ischemia/Reperfusion Injury in Female Mice. Front Pharmacol. 2021; 12:654316. PMC: 8369344. DOI: 10.3389/fphar.2021.654316. View

4.
Teng Y, Yi J, Chen J, Yang L . N6-Methyladenosine (m6A) Modification in Natural Immune Cell-Mediated Inflammatory Diseases. J Innate Immun. 2023; 15(1):804-821. PMC: 10673353. DOI: 10.1159/000534162. View

5.
Zhang C, Chen L, Peng D, Jiang A, He Y, Zeng Y . METTL3 and N6-Methyladenosine Promote Homologous Recombination-Mediated Repair of DSBs by Modulating DNA-RNA Hybrid Accumulation. Mol Cell. 2020; 79(3):425-442.e7. DOI: 10.1016/j.molcel.2020.06.017. View